Latest Regenerative June 1, 2025 News

Trailhead Biosystems launches iPSCs for blood-brain barrier and neurological research

Researchers may now have a new tool to unlock insights into blood-brain barrier regulation and neurological disease mechanisms.

With FDA approval secured, Ensoma prepares to advance its groundbreaking in vivo therapy into clinical trials targeting X-CGD patients.

The Phase 2 trial RCT will evaluate adverse event and efficacy endpoints.

TreeFrog has developed a proprietary iPSC manufacturing process called C-Stem, moving one step closer to human trials.

This small German biotech company is joining the knee OA stem cell race.